重大资产重组草案出炉！拟17亿收购“小巨人”

Core Viewpoint - Lidman plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, aiming to enhance its position in the biopharmaceutical industry and improve financial performance [2][5][7]. Group 1: Transaction Details - The acquisition involves cash payment for 70% equity of Xiansheng Xiangrui, with a transaction value of 1.733 billion yuan [2]. - The assets of Xiansheng Xiangrui exceed 50% of Lidman's total assets, constituting a major asset restructuring [3]. - Following the transaction, Lidman will consolidate Xiansheng Xiangrui into its financial statements [2][7]. Group 2: Company Background - Lidman specializes in the research, production, and sales of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [4]. - Xiansheng Xiangrui, a member of Xiansheng Investment Group, focuses on biopharmaceuticals, particularly in vitro diagnostic reagents and vaccines, with a strong market position in tuberculosis screening [4][5]. Group 3: Financial Impact - The acquisition is expected to enhance Lidman's revenue and net profit, improving its overall financial condition [6][7]. - Projected revenues for Xiansheng Xiangrui are 6.53 billion yuan, 5.82 billion yuan, and 2.28 billion yuan for 2023, 2024, and the first three quarters of 2025, respectively [6][7]. - Xiansheng Xiangrui has committed to achieving a minimum net profit of 1.66 billion yuan, 1.86 billion yuan, and 2.08 billion yuan for the years 2025, 2026, and 2027 [7].